Literature DB >> 19143653

Mutant models for genes associated with schizophrenia.

Lieve Desbonnet1, John L Waddington, Colm M P O'Tuathaigh.   

Abstract

Schizophrenia is a highly complex and heritable psychiatric disorder in which multiple genes and environmental factors interact to cause the schizophrenia phenotype. A new generation of molecular studies has yielded numerous candidate genes with a putative role in risk for schizophrenia, whereas other genes regulate putative pathophysiological mechanisms. Mutant mice having either deletion (knockout) or insertion (knockin/transgenesis) of schizophrenia risk genes now allow the functional role of these genes to be investigated. In the present mini-review, we outline the advantages and limitations of various approaches to phenotypic assessment of mutant mouse models, including ethologically based methods. Thereafter, we consider recent findings, with a particular focus on, first, dopaminergic and glutamatergic pathophysiological models and, secondly, putative roles for DISC1 (disrupted in schizophrenia 1) and NRG1 (neuregulin 1) as susceptibility genes for schizophrenia. Finally, we identify current challenges associated with the use of genetic mutant models and highlight their potential value for exploring gene-gene and gene-environment interactions in relation to schizophrenia.

Entities:  

Mesh:

Year:  2009        PMID: 19143653     DOI: 10.1042/BST0370308

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  18 in total

Review 1.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

3.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

Review 4.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

Authors:  Caline S Karam; Jacob S Ballon; Nancy M Bivens; Zachary Freyberg; Ragy R Girgis; José E Lizardi-Ortiz; Sander Markx; Jeffrey A Lieberman; Jonathan A Javitch
Journal:  Trends Pharmacol Sci       Date:  2010-06-25       Impact factor: 14.819

6.  Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.

Authors:  Antonio Ortega-Alvaro; Auxiliadora Aracil-Fernández; María S García-Gutiérrez; Francisco Navarrete; Jorge Manzanares
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

Review 7.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 8.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

10.  Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk.

Authors:  Peter L Oliver; Kay E Davies
Journal:  Hum Mol Genet       Date:  2009-09-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.